Risk Factors Update Summary
- Lead compound changed from "lirentelimab" to "AK006" in multiple instances, indicating a shift in focus.
- Net losses increased from $185.7 million in 2022 to $320.0 million in 2023, a significant rise.
- Cash, cash equivalents, and marketable securities decreased from $279.8 million to $170.8 million.
- Workforce reduced significantly with 123 full-time employees at December 31, 2022.
- Gross U.S. federal and state net operating loss carryforwards decreased from $893.7 million to $847.2 million.
- The market price of common stock decreased from $195.43 to $51.95 as of March 8, 2024.
- The number of employees engaged in research and development decreased from 91 to an unspecified number.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1564824&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.